Supply Chain Intelligence

Immix Biopharma, Inc. Supply Chain

IMMX supply chain intelligence for Immix Biopharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

IMMX ·Last updated 2026-10-28 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

9Suppliers
0Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Immix Biopharma, Inc. (IMMX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

13Total relationships
5Distinct source URLs
11High confidence
0.858Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Immix Biopharma, Inc. Suppliers

TickerNameConfidenceEvidence
CITIZENS-JMP-SECURITIES-LLC CITIZENS-JMP-SECURITIES-LLC 92% On March 25, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”) and Citizens JMP Securities, LLC entered into Amendment No. 1 ("Amendment No. 1") to that certain At The Market Offeri…
U-S-MEDICAL-RESEARCH-FOUNDATION U-S-MEDICAL-RESEARCH-FOUNDATION 92% In August 2024, the Company entered into a Patent License Agreement with a U.S. medical research foundation pursuant to which the Company was granted certain exclusive and nonexclusive licenses and s…
BIRAD-RESEARCH-AND-DEVELOPMENT-COMPANY-LTD BIRAD-RESEARCH-AND-DEVELOPMENT-COMPANY-LTD 90% Pursuant to the Agreement, Nexcella paid the Licensors an upfront fee of $1,500,000 in December 2022.
HADASIT-MEDICAL-RESEARCH-SERVICES-DEVELOPMENT-LT HADASIT-MEDICAL-RESEARCH-SERVICES-DEVELOPMENT-LT 90% Pursuant to the Agreement, Nexcella paid the Licensors an upfront fee of $1,500,000 in December 2022.
NEXCELLA-INC NEXCELLA-INC 90% Research and License Agreement entered into on November 27, 2022 by and between Nexcella, Inc. (formerly Immix Biopharma Cell Therapy, Inc.), Hadasit Medical Research Services & Development, Ltd. and…
THIRD-PARTY-CONTRACT-MANUFACTURERS THIRD-PARTY-CONTRACT-MANUFACTURERS 80% We do not have any long-term manufacturing and supply agreements with our third-party contract manufacturers, but we enter into specific contracts on an as needed basis for individual batch productio…
THIRD-PARTY-CONTRACT-ORGANIZATIONS THIRD-PARTY-CONTRACT-ORGANIZATIONS 80% The Company has made certain accounting policy elections whereby it (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months or less) and (…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from IMMX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IMMX graph: Reciprocal relationship from JNJ grap…
CONTRACT-RESEARCH-ORGANIZATIONS CONTRACT-RESEARCH-ORGANIZATIONS 70% The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including... contract manufa…

Immix Biopharma, Inc. Customers

No clients on recordImmix Biopharma, Inc. does not appear to disclose named customer relationships in its verified regulatory filings. Many companies do not publicly name customers in regulatory disclosures.

Immix Biopharma, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IMMX-DEBT Debt stack $1.0M 90% Market cache reports total debt of $1.0M.
IMMX-DEBT-10240 Warrants outstanding: 31500 90% xbrl warrant detail from xbrl 2026-03-31.
IMMX-DEBT-10241 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.

Immix Biopharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Immix Biopharma, Inc..

Immix Biopharma, Inc. Ownership

HolderNameConfidenceEvidence
IMMX-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 77 tracked holders.

Immix Biopharma, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
JNJ Johnson & Johnson 100.00 1 ['supplier']
ANIK Anika Therapeutics, Inc. 50.00 2
DYAI Dyadic International, Inc. 50.00 2
AORT Artivion, Inc. 50.00 2
AVBP ArriVent BioPharma, Inc. 50.00 2
CYTOF Altamira Therapeutics Ltd. 50.00 2
ENGNW enGene Therapeutics Inc. 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
FCX Freeport-McMoRan Inc. 50.00 2
CBIH Cannabis Bioscience International Holdings, Inc. 50.00 2
BNR Burning Rock Biotech Limited 50.00 2
BNRG Brenmiller Energy Ltd 50.00 2
AVTX Avalo Therapeutics, Inc. 50.00 2
CSTE Caesarstone Ltd. 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
CVRX CVRx, Inc. 50.00 2
SNNUF Smith & Nephew plc 50.00 2
ALC Alcon Inc. 50.00 2
ATNM Actinium Pharmaceuticals, Inc. 50.00 2
BLLN BillionToOne, Inc. 50.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Immix Biopharma, Inc..

Unlock full IMMX data, View plans →
ChainSifter · Guerilla Finance support@chainsifter.com Terms Disclaimer ← Back to Map
🔐
IMMX
Unlock IMMX Supply Chain Data
Verified relationships include:
CITIZENS-JMP-SECURITIES-LLCCITIZENS-JMP-SECURITIES-LLCSupplier92%
U-S-MEDICAL-RESEARCH-FOUNDATIONU-S-MEDICAL-RESEARCH-FOUNDATIONSupplier92%
+9 more relationships locked
Subscribe, View plans →
Already a subscriber? Sign in →